Layout Table~~~~1405~1405~~

Emerging Markets for Microfluidic Applications~
Published by Yole Développement, May 2007

Microfluidics is becoming a key technology integrated in most of Life Science companies’ development roadmap. Drug discovery remains today the first microfluidics market. Microfluidics key advantage is to enable higher analysis throughput while decreasing analysis time and cost. Firstly used at the system level for liquid handling, microfluidics technology is also successfully integrated in cartridges for research applications. Commercialised by SME and big instrumentation companies, microfluidics products are bound to be part of the gold standard technologies used in research applications.~Published by Yole Développement, May 2007

Drug discovery remains today the first microfluidics market. Microfluidics key advantage is to enable higher analysis throughput while decreasing analysis time and cost. Firstly used at the system level for liquid handling, microfluidics technology is also successfully integrated in cartridges for research applications. Commercialised by SME and big instrumentation companies, microfluidics products are bound to be part of the gold standard technologies used in research applications.

The microfluidics market for research applications will steadily grow in the 5 coming years, but the double digit growth will come from the diagnostic market. Indeed microfluidics has a strong competitive advantage in this market enabling analysis automation and decentralisation, but also in facilitating the molecular diagnostic emergence and success.

Microfluidics components for diagnostic are expected to reach €1b market value in 2011 with a Total Accessible Market of about 5b€.

If microfluidics proof of concept is validated now, no real standard has been defined yet. Dedicated to research applications, microfluidics products are rather produced in low volume. The microfluidics penetration in the diagnostic market will require the technology validation from a manufacturability point of view. Only the technologies fitting with the diagnostic market cost and regulation pressure will success.

Such standardisation will lead to a structuration of the industrial food chain. New players are entering the field. Some microfluidics companies adapt their business model to the market evolution. Mergers and acquisitions are also increasing.

Most of diagnostic companies have positioned microfluidics in their development roadmap as a key technology to support their growth strategy.

Indeed microfluidics is clearly identified as an enabling technology to support the development of the point of care and the molecular biology markets.

All ingredients are gathered for success:

1 - Microfluidics is overcoming the proof of concept milestones. Some companies are today positioned in microfluidics industrialisation

2 - Microfluidics provides the expected technical solutions required in the diagnostic market evolution

3 - Innovative high tech companies are entering the diagnostic field. They will participate to the market dynamism in facilitating convergence of technologies like microfluidics and biomarkers.~Emerging Markets for Microfluidic Applications (Single User License)|1052|Emerging Markets for Microfluidic Applications (Corporate License)|1176|Emerging Markets for Microfluidic Applications (Corporate Multi Site License)|1177|~1405~3200~~

MicroReaction Technology~
Published by Yole Développement, February 2007

The report presents the industry status of microreaction market, with players, their business models, products but it also describes the applications of the technology and the status of involvement of the fine chemical and pharmaceutical industry in this technology.~Published by Yole Développement, February 2007

The report presents the industry status of microreaction market, with players, their business models, products but it also describes the applications of the technology and the status of involvement of the fine chemical and pharmaceutical industry in this technology.

MicroReaction Technology (MRT), a solution for process intensification, is evolving from R&D lab use to chemicals production, leading to new products and new companies’ strategies, which widen technology possibilities and increases users’ number.

The change of paradigm from batch production to continuous flow is occurring. Indeed, 20 to 30 chemical plants are now running with microstructured elements. Large chemical and pharmaceutical companies are increasingly considering MRT as a process intensification solution to solve some of their current processing problems for lab research and debottlenecking production.

The current market for microreaction products is low, but exponential potential is forecasted in the coming years, provided that proof of technical and economical efficiency drives the change of paradigm.

Currently, microreaction modules sold as stand-alone modules account for 50% of the market, the other half being the sale of integrated systems. Fine & specialty chemicals businesses represent the largest part of MRT market which is today at its beginning. The wider use of MRT is going behind fine & specialty chemicals frontiers to pharmaceuticals, commodity chemicals and petrochemicals. Major MRT players as the Institute fur Mikrotechnik Mainz (IMM) and its spin-offs CPC, Mikroglas, Ehrfeld BTS, but also Syrris and Velocys are ever gaining new customers. However, new players are entering the market presenting new offers.

Who should buy the report:

• Executives of companies active in the development of microreaction products or assessing their entry in this field


• Executives of engineering companies, that could broaden their process intensification offer with microreaction


• R&D managers or Production leaders of chemical companies, that want to discover a new technology (products, players, market)

~MicroReaction Technology (Single User License)|1049|MicroReaction Technology (Corporate License)|1178|MicroReaction Technology (Corporate Multi Site License)|1179|~1405~3194~~

The Global Biotech Report 2006: The rise of the Biotech blockbusters~
Published by Visiongain, September 2006

IThe report provides you with in-depth market analysis for all top-selling current and major potential products to arrive before the decade ends. The report extensively identifies biopharmaceuticals market potential by analysing the latest clinical trial research. The study also examines the challenges faced by potential biotech companies and opportunities newcomers to the arena. This is the industry's premier report. Numbers are strictly limited, so order today.~Published by Visiongain, September 2006

It is here. The industry's leading Annual Biotech report has just been announced. Only 20 copies are available. So order your copy today.

In stark contrast to the rest of the pharmaceutical industry, the world market for biotech drugs is thriving. In 2005, biotech revenues reached $60bn and visiongain predicts that this will continue - YOU MUST BE PART OF THIS SUCCESS NOW. Order a copy of visiongain’s new report to get the details.

Having grown 16.5 per cent from 2004's revenues, double-digit growth of the market will continue to the end of the decade. You need to be aware of how you can succeed in this area. 1 report will tell you all you need to know. SO order this report NOW.

- Over 250+ pages
- Over 150 tables and figures
- Global revenues & growth rates for the leading biotech drugs
- Company profiles of the leading biotech firms
- A comprehensive analysis of the global market, 2005-2011
- Revenue forecasts for the leading biotech drugs
- Revenues into therapeutic area
- Pipeline treatments
- A geographic breakdown of the market
- A Focus on biogenerics

Designed as an essential business aid, The Global Biotech Report 2006 provides the leading thorough evaluation of your market.

The report provides you with in-depth market analysis for all top-selling current and major potential products to arrive before the decade ends. The report extensively identifies biopharmaceuticals market potential by analysing the latest clinical trial research. The study also examines the challenges faced by potential biotech companies and opportunities newcomers to the arena. This is the industry's premier report. Numbers are strictly limited, so order today.

Five key questions this report answer's are:
1. What are the market values of the major therapeutic areas of the global biopharmaceutical market by product from, 2005 to 2011?
2. Who are the major companies involved in the world market today and in the future, and will they be competition to you?
3. How imminent are biogenerics and what is their potential market value?
4. What strategies can be used to maximise your profits in terms of the major challenges facing biotech?
5. What's in the 2006 biopharmaceutical pipeline and what revenues can they reach by 2011?

Due to visiongain's targetted consultancy work in the area, only a strict 20 copies of the report are issued. Please order your copy now so as you do not miss out. Copies will be reserved on a strictly first-come-first-serve basis. So please contact us now.

This report is a vital addition to gaining an understanding of this highly profitable market sector and will give your company 'the edge' of your competitors. You can not afford to be without this report from visiongain.

Table of Contents ~The Global Biotech Report 2006%3A The rise of the Biotech blockbusters (Single user License PDF)|905|The Global Biotech Report 2006%3A The rise of the Biotech blockbusters (Department License PDF)|906|The Global Biotech Report 2006%3A The rise of the Biotech blockbusters (Company wide license PDF)|907|~1405~2992~~

LifescienceIC~
Published by Yole Développement, April 2006

The purpose of the report is to provide a better understanding of Life Sciences to semi-conductor and MEMS companies, with a detailed analysis of the different application fields, market evaluation and strategy analysis for semiconductor and MEMS companies. This report presents and describes the biological challenges ins and out. It highlights the specificities of the different Life Science industries and the business opportunities for semiconductor and MEMS companies. It also answers the question: “how could IC and MEMS companies become a key leader of the Life Sciences field?”~Published by Yole Développement, April 2006

A very futuristic approach of Life Sciences is on the way. New in vitro diagnostics systems, new therapy strategies, genetic diseases treatment, targeted and intelligent drug delivery, artificial pancreas… are health improvement promised to the future generations, enabled by semiconductor and MEMS technologies. The Life Sciences industry is already facing very important challenges to take its way to this expected innovation breakthrough.

Such future of Life Sciences will be possible by bringing together many different technologies like microelectronics, mechanics, optics, physics, molecular biology… Indeed microelectronics that has led to the explosion of consumer electronics sales could now bring its added value to different to the Life Science applications. The key challenge for microelectronics is to make complexity invisible, to make technology accurate, reproducible and intuitive for a natural use. They are already used for drug delivery dedicated products.

This expected evolution in the Life Sciences field requires thus teams from different background to collaborate and to understand the challenges each other is facing in its own domain. It involves being able to understand the biological ins and out as well as challenges to work together in identifying an innovative solution to propose.

To take part in this innovation process, it is very important to understand the technology and industrial trends by having a good view on the current technologies used, their limits and advantages, the applications and the way Life Science is working.

The Life Sciences field is considered as a very attractive field to target for the next innovation to launch. Some companies already succeed as shows the Affymetrix success story. In a little more than 10 years, using its technology coming from the semiconductor field and with key agreements with Life Science companies (Roche, Novartis, Aventis, BMS, bioMérieux…), Affymetrix is now dominating the biochip market worldwide with more than 70% market shares.

Several semiconductor companies are involved in Life Sciences like STMicroelectronics, Philips, Agilent… and several others have stopped their activity like Motorola, Infineon… Entering the Life Sciences field could be complex since it is a very broad field including many different industries like drug discovery, in vitro diagnostic, medical devices, instrumentation…

The market is much segmented in term of applications, technologies and medical use. Each field has its own specificity in term of industry organization, added value chain, industrial players, R&D activities, drivers and market entry barriers, entry point in the supply chain, position in the value chain… For example, selling devices is not always the best way to maximise the added value compared to a module/function approach. One of the main challenges in entering the Life Sciences field is to define the value of the technology to propose in this business.

The purpose of the report is to provide a better understanding of Life Sciences to semi-conductor and MEMS companies, with a detailed analysis of the different application fields, market evaluation and strategy analysis for semiconductor and MEMS companies.

This report presents and describes the biological challenges ins and out. It highlights the specificities of the different Life Science industries and the business opportunities for semiconductor and MEMS companies. It also answers the question: “how could IC and MEMS companies become a key leader of the Life Sciences field?”

LifescienceIC report will introduce you to molecular biology with basic concepts presentation so that you get a better understanding of the biology field and challenges. We particularly describe biological compounds (nucleic acids, proteins, peptides, glycanes etc...), their size scales and interaction to highlight and make understandable the biological complexity.

A part of this report is also dedicated to the different existing techniques used today in molecular biology. We highlight the gold standard technologies per application field. Such information is required to get a technological and commercial competitive advantage. Sample preparation, PCR amplification, nucleic acids and proteins separation and detection, immunoassays, HPLC columns and mass spectrometry are examples of technologies described.

The industrial fields where semiconductor technology could be used will be presented, highlighting the market potential ($), players involved, and key specificities. The report also defines the attractive functions from semiconductor devices. It is illustrated by current products and developments.~LifescienceIC (Single User License)|1047|LifescienceIC (Corporate License)|1180|LifescienceIC (Corporate Multi Site License)|1181|~1405~3191~~

World Guide to Pharmaceutical Industry 2005, 4th ED~
Published by Bioseeker Group, August 2005

The 4th Edition of World Guide to Pharmaceutical Industry contains almost 3,000 profiles on drug developing companies from over 50 different nations. This edition has not only been updated but it has also been strengthened with a special inclusion and research on more than 200 drug delivery companies.

Companies are described by all their targeted therapeutic areas, short profile, contact information, web and email address. To reflect changes we have included a separate list of companies who have either filed for bankruptcy, undergone M&A etc.~Published by Bioseeker Group, August 2005

The 4th Edition of World Guide to Pharmaceutical Industry contains almost 3,000 profiles on drug developing companies from over 50 different nations. This edition has not only been updated but it has also been strengthened with a special inclusion and research on more than 200 drug delivery companies.

Companies are described by all their targeted therapeutic areas, short profile, contact information, web and email address. To reflect changes we have included a separate list of companies who have either filed for bankruptcy, undergone M&A etc.

The World Guide to Pharmaceutical Industry is based on BioSeeker's proprietary CD-ROM technology which includes smart database structure, find and sort options, internet and email interactivity. All companies are provided with links, which connect you directly to the company webpage for further research. Companies can be further researched on from inside the application by linking search queries directly to search engines like Google and PubMed. Hence, World Guide to Pharmaceutical Industry brings important information closer to you from any one source. Found information on the CD-ROM may easily be shared with others over email or in print.

World Guide to Pharmaceutical Industry was created for professionals within the industry and for those with particular interest of the pharmaceutical industry, i.e. investors, trade organizations, and associated industry to that of pharmaceutical industry. Whether you are a CEO, business developer, in/out licensing officer, venture capitalist, consultant etc. you will find World Guide to Pharmaceutical Industry useful to locate M&A candidates, customers, collaboration partners, competitors etc.~World Guide to Pharmaceutical Industry 2005, 4th ED%3A CD Version|217|~1405~1795~~

The World Biotech Market 2005~
Published by Visiongain, June 2005

The biopharmaceutical market has undergone rapid expansion since its emergence thirty years ago. No longer is the market confined to growth hormones, insulin and red blood cell stimulating agents. Innovative science driven by the 2001 human genome project is accelerating the market into targeting a huge range of diseases from growth deficiency to arthritis to multiple sclerosis and orphan diseases such as Fabry's disease.~ Published by Visiongain, June 2005

The biopharmaceutical market has undergone rapid expansion since its emergence thirty years ago. No longer is the market confined to growth hormones, insulin and red blood cell stimulating agents. Innovative science driven by the 2001 human genome project is accelerating the market into targeting a huge range of diseases from growth deficiency to arthritis to multiple sclerosis and orphan diseases such as Fabry's disease.

Visiongain values the 2005 biopharma market at $70.8bn. Having grown 16.5% from 2004's revenues of $60.7bn, double-digit growth of the market will continue to the end of the decade. Composed of 9 major therapeutic areas including oncology, anti-infectives, vaccines and the market leader blood disorders, the market by 2010 is expected to represent 17% of all prescriptions written compared with 2004's 12%. At this pace of growth, biotech is now outgrowing Big Pharma. At present the US dominates the biotech market and will do so for the rest of the forecast period. Japan and the EU will see a fall in global market share, whilst the Asia-Pacific region will see high levels of unprecedented growth.

Biotech companies however still face major challenges. The threat of the emergence of biogenerics is mounting, with 11 products facing patent expiry before 2007- 5 of which are blockbusters. The Australian approval of his Sandoz's Omnitrope hGH product is paving the way, and increasing pressure upon EU and US regulatory agencies to give the go ahead to biogenerics. Designed as an essential business aid, World Biotech, 2005 provides a thorough and evaluation of the market that is of excellent value. This extensive report has the following chapter headings:

1. Executive Summary of the World Biotech Market
2. An Introduction to Biopharmaceuticals
3. Diseases treated by Biopharmaceuticals
4. Overview of Biopharmaceuticals Market, 2003-2004
5. Company Revenues and Market Share, 2004
6. Biopharmaceutical Pipeline, 2005
7. Biopharmaceutical Market Forecast by Therapeutic Area, 2003-2010
8. Summary of 2010 Biopharmaceuticals Market
9. Introduction to Biogenerics
10. The Potential Biogeneric Market
11. Biopharmaceutical Market Challenges
12. Venture Capitalism and Biotech
13: The Global Biopharmaceutical Market by Region, 2003-2010
14: The Human Genome Project and Its Influence on the Biotech Industry
15: Conclusion: Big Pharma Must Invest into the Biotech Arena

The report provides in-depth market analysis for all top-selling current and major potential products to arrive before the decade ends. The report extensively identifies biopharmaceuticals market potential by analysing the latest clinical trial research. The study also examines the challenges faced by potential biotech companies and opportunities newcomers to the arena

Why You Must Buy This Report?

This 262 paged report spanning 15 chapters features over 80 tables, 85 graphs and charts, news, insights and the latest developments. Over 120 companies are mentioned in this up-to-date report, which reviews 2004 revenues for all the biopharmaceutical products featured within the market.

Table of Contents
Report Overview

~The World Biotech Market 2005 (Single user License PDF)|206|The World Biotech Market 2005 (Department License PDF)|700| The World Biotech Market 2005 (Company wide license PDF)|971|~1405~1884~~

Bio-Distributors China 2005~
Published by General Biologic, March 2005

Bio-Distributors China 2005 is the essential resource for life science suppliers seeking to reach customers in China. It is the first and only comprehensive overview, analysis, and directory of reagent, consumable, and laboratory and equipment distributors in China. The report contains an overview and analysis of the life science distribution industry as well as its evolution. The detailed directory of approximately 180 distributors provides contact information, market segment, and brands distributed for each distributor listed. Also included is a helpful manufacturer's guide with tips on how to successfully distribute products and manage your distribution channel in China.~Published by General Biologic, March 2005

The purpose and scope of this report is to provide a comprehensive resource for life science suppliers distributing products to Chinese life scientists. Includes:
• An overview and analysis of the life science distribution industry and its evolution,
• A manufacturer's guide with tips on how to successfully distribute products and manage distributors
• The results from an end user survey and associated analysis
• A detailed directory of nearly 250 distributors, 2 case studies, and more than 10 profiles of distributors with

    o English name
    o Chinese name
    o Brands distributed
    o Contact information
    o Geography covered
    o Segment classification

Who benefits from this report?

• Suppliers of life science equipment, reagents, and consumables interested in distributing products to China, engaged in distribution deals with a Chinese distributor, or initiating or expanding their presence in China

Why is this report unique?

• This report contains the only comprehensive overview, analysis, and directory of life science supply distributors in China

Methodology and information sources

     • Extensive face-to-face and phone interviews
     • Chinese distributors
     • Foreign manufacturers
     • Industry experts
     • Survey of Chinese end users
     • Secondary sources
     • Internet
     • Academic publications

Table of Contents ~ Bio-Distributors China 2005|216|~1405~1794~~